ProQinase GmbH Partners with Cell Signaling Technology, Inc. to Co-Promote and Distribute Kinase Assays and Enzymes to the Drug
The integration of ProQinase's high quality enzymes with CST's premier phospho-specific antibody reagents will create value-added assay systems that will facilitate kinase inhibitor drug discovery, lead optimization and profiling.
There are over five hundred human protein kinases that transduce signals via protein phosphorylation and are critical regulators of innumerable cellular processes. A significant number of kinases have been implicated in human diseases, including cancer, inflammatory, metabolic and cardiovascular diseases. This has made protein kinases a major focus for pharmaceutical drug discovery. Successful kinase drug discovery requires validated and optimized reagents for target discovery and validation, high throughput screening (HTS) and therapeutic development. Critical reagents for this effort are high affinity phospho-specific antibodies and active, purified kinase enzymes for HTS drug discovery and lead compound specificity profiling.
"Cell Signaling Technology is decidedly the best partner for ProQinase " said Christoph Sachsenmaier, ProQinase's Head of Business Development. "We are very excited about this partnership and strongly believe that CST´s renowned expertise in antibody development and ProQinase´s strength in producing large quantities of highly active kinase enzymes will strongly impact the drug discovery and research market. Through this partnership we will be able to serve our customers faster and with a more comprehensive product portfolio".
"We are excited about joining forces with ProQinase to develop valuable solutions for kinase drug discovery", added Christopher Bunker, CST's Director of Business Development. "ProQinase has the reputation for superior kinase products and services that is an ideal fit with Cell Signaling Technology's expertise and market leadership in phospho-specific antibodies. Our combined high performance reagents will enable research and drug discovery scientists to more rapidly discover and develop important new kinase inhibitors leading to targeted therapeutic treatments for a range of human diseases."
Other news from the department business & finance
These products might interest you
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous